Scholarlink

Purpose <p>Binge Eating Disorder (BED) is a prevalent condition with limited evidence-based treatments. Naltrexone and Bupropion Combination (NB) targets neurobiological pathways implicated in BED. The Objective of this paper is to evaluate the efficacy of NB for BED in adults through a systematic review and meta-analysis.</p> Methods <p>Following PRISMA guidelines, we searched major databases and trial registries (up to Feb 2025) for randomized controlled trials (RCTs) comparing NB to placebo or usual care in adults with BED. The primary outcome was binge eating frequency; secondary outcomes included weight loss and BMI. Risk of bias (ROB2) and certainty of evidence (GRADE) were assessed. A fixed-effects meta-analysis was performed.</p> Results <p>Four RCTs (n = 444 participants) met inclusion criteria. Meta-analysis of three studies indicated NB did not significantly reduce binge eating frequency compared to controls (Mean Difference [MD] −&#xa0;1.49, 95% CI −&#xa0;3.63 to 0.64, p = 0.17). However, NB significantly reduced weight (MD -3.57&#xa0;kg, 95% CI −&#xa0;4.86 to −&#xa0;2.27, p &lt; 0.001) and BMI (MD −&#xa0;1.24&#xa0;kg/m<sup>2</sup>, 95% CI −&#xa0;1.79 to −&#xa0;0.70, p &lt; 0.001). The certainty of evidence was assessed as moderate for binge frequency and low for weight and BMI outcomes.</p> Conclusion <p>NB aids weight reduction in adults with BED, but current evidence is insufficient to confirm its efficacy for reducing binge eating frequency. Further high-quality RCTs are warranted.</p> Level of evidence <p>Level I, systematic reviews and meta-analyses.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of naltrexone and bupropion combination in patients with binge eating disorder: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Seyedeh Narjes Roudbaraki,
  • Mostafa Salimi,
  • Sina Esmailpour,
  • Farzaneh Mohammadi

摘要

Purpose

Binge Eating Disorder (BED) is a prevalent condition with limited evidence-based treatments. Naltrexone and Bupropion Combination (NB) targets neurobiological pathways implicated in BED. The Objective of this paper is to evaluate the efficacy of NB for BED in adults through a systematic review and meta-analysis.

Methods

Following PRISMA guidelines, we searched major databases and trial registries (up to Feb 2025) for randomized controlled trials (RCTs) comparing NB to placebo or usual care in adults with BED. The primary outcome was binge eating frequency; secondary outcomes included weight loss and BMI. Risk of bias (ROB2) and certainty of evidence (GRADE) were assessed. A fixed-effects meta-analysis was performed.

Results

Four RCTs (n = 444 participants) met inclusion criteria. Meta-analysis of three studies indicated NB did not significantly reduce binge eating frequency compared to controls (Mean Difference [MD] − 1.49, 95% CI − 3.63 to 0.64, p = 0.17). However, NB significantly reduced weight (MD -3.57 kg, 95% CI − 4.86 to − 2.27, p < 0.001) and BMI (MD − 1.24 kg/m2, 95% CI − 1.79 to − 0.70, p < 0.001). The certainty of evidence was assessed as moderate for binge frequency and low for weight and BMI outcomes.

Conclusion

NB aids weight reduction in adults with BED, but current evidence is insufficient to confirm its efficacy for reducing binge eating frequency. Further high-quality RCTs are warranted.

Level of evidence

Level I, systematic reviews and meta-analyses.